Loading clinical trials...
Loading clinical trials...
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Temporomandibular Disorders (TMD)
Conditions
Interventions
Rimegepant
Placebo
Locations
32
United States
Bruce Nelson, DDS
Phoenix, Arizona, United States
Arizona Research Center
Phoenix, Arizona, United States
The Medici Medical Research, LLC
Hollywood, Florida, United States
The Medici Medical Research
Hollywood, Florida, United States
SouthCoast Research Center, Inc
Miami, Florida, United States
SouthCoast Research Center
Miami, Florida, United States
Start Date
May 5, 2022
Primary Completion Date
May 18, 2023
Completion Date
May 18, 2023
Last Updated
May 16, 2024
NCT07445516
NCT06617494
NCT07022795
NCT06760884
NCT07371195
NCT06781138
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions